WEE1 and hepatocellular carcinoma: Small molecular agents including Doramapimod_1042, JAK1_8709_1718, AZD2014_1441, SB505124_1194, NU7441_1038, ML323_1629, MK-1775_1179, Lapatinib_1558, Sepantronium bromide_1941, Afatinib_1032, Paclitaxel_1080, WEHI-539_1997, and Wee1 Inhibitor_1046 exhibited the notable difference in IC50 between low- and high-risk HCC patients (Fig. 6A), which might potentially treat HCC.